EMA guideline: no way...: [Design Issues]

posted by mittyri  – Russia, 2019-12-07 21:58 (2018 d 02:03 ago) – Posting: # 20959
Views: 9,481

Dear Osama,

❝ I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?


I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
19 visitors (0 registered, 19 guests [including 15 identified bots]).
Forum time: 01:02 CEST (Europe/Vienna)

Law is mind without reason.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5